Clinical Trial Update: PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab (PD-1 inhibitor) combined with capecitabine as adjuvant treatment after radical resection of cholangiocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Sintilimab (sintilimab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Cholangiocarcinoma | Phase 2 | Status: UNKNOWN